TANG KEVIN purchased $244K of BOLD (indirect holdings)

TANG KEVIN purchased 103,612 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.36 ($2.32–$2.40, $0.24M total) across 3 trades over 2026-11-18 to 2026-11-20. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Nov 21, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

This provides a fresh, company-specific datapoint on insider buying activity, but it does not include any new business, financial, or regulatory information that would directly reset valuation assumptions.

02

Market read

Traders may treat the filing as a modest bullish sentiment input, but it is unlikely to be a standalone catalyst for a large repricing.

03

What to watch

Because the article is only an insider transaction, traders should avoid extrapolating to near-term earnings or clinical/regulatory catalysts without additional company-specific news.

Relevance 5/10Novelty 5/10Timing: filed 2026-11-20, covering purchases from 2026-11-18 to 2026-11-20

Background

The article is an SEC Form 4 insider transaction disclosure for Boundless Bio, Inc. (BOLD) by Tang Kevin, a 10% owner, reported as indirect holdings.

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

Boundless Bio disclosed a Form 4 showing 10% owner Tang Kevin bought 103,612 shares indirectly for about $244.2K at $2.32 to $2.40.

Expected impact

Likely mild upward bias or no immediate move as traders weigh the signal against the modest size and indirect nature of the purchase.

Evidence & confidence

The filing is a primary SEC Form 4 and is specific about trade dates, share count, and price range, but the transaction value (~$244K) is small versus typical market-moving thresholds and provides no new operating or guidance catalyst.

Market effects

No clear sector read-through from a single small insider purchase.

None.

None.

Counterpoint

Indirect holdings and a non-10b5-1 plan do not guarantee a fundamental change; the purchase could reflect diversification, liquidity needs, or pre-existing arrangements not captured here.

Key entities

  • Boundless Bio, Inc.

    US-listed biotech subject of the Form 4 insider purchase disclosure.

  • Tang Kevin

    10% owner reporting open-market purchases reported via indirect holdings.

  • Tang Capital Management LLC

    Joint filer listed as a 10% owner.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.